Mangoceuticals, Inc. Common Stock Total Liabilities
Mangoceuticals, Inc. Common Stock total liabilities. Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has total liabilities worth $1.65 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Mangoceuticals, Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Mangoceuticals, Inc. Common Stock (2021–2025)
Total liabilities of Mangoceuticals, Inc. Common Stock from 2021 to 2025. This chart illustrates how Mangoceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Mangoceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Throgmorton Trust Plc
LSE:THRG
|
UK | GBX6.49 Million |
|
Marvel Biosciences Corp
V:MRVL
|
Canada | CA$4.33 Million |
|
Schroder Japan Growth Fund
LSE:SJG
|
UK | GBX3.69 Million |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
UK | GBX93.06 Million |
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
USA | $9.13 Million |
|
Quantum Genomics SA
PA:ALQGC
|
France | €2.81 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Mangoceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Mangoceuticals, Inc. Common Stock assets under control.
Liquidity & Leverage Metrics
Mangoceuticals, Inc. Common Stock Total Liabilities Ratios Explained
Mangoceuticals, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mangoceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mangoceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Mangoceuticals, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $890.57K | -37.52% |
| 2024-12-31 | $1.43 Million | +416.40% |
| 2023-12-31 | $276.04K | -29.09% |
| 2022-12-31 | $389.26K | +891.23% |
| 2021-12-31 | $39.27K | -- |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more